Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
83 hedge funds and large institutions have $280M invested in Marinus Pharmaceuticals, Inc in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
44% more call options, than puts
Call options by funds: $4.11M | Put options by funds: $2.85M
11% more funds holding
Funds holding: 75 → 83 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
21% less capital invested
Capital invested by funds: $355M → $280M (-$75.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$2.75M |
| 2 |
BL
Bleichroeder LP
New York
|
+$2.58M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.42M |
| 4 |
AC
Antara Capital
New York
|
+$1.89M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.88M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2.04M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.95M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.54M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1M |
MRNS Hedge Fund Activity: Q1 2022 in Review
83 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q1 2022, worth a combined $280M — down 21% from $355M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new MRNS positions and 10 closed out — a net gain of 8 holders — while 22 added to existing stakes and 25 trimmed.
The largest buyer was VR Adviser, adding an estimated $2.75M. The largest seller was BlackRock, cutting an estimated $3.88M.
- 83 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q1 2022, up from 75 in Q4 2021.
- Funds reported $280M of Marinus Pharmaceuticals, Inc stock for Q1 2022, down 21% quarter-over-quarter.
- 18 funds opened new Marinus Pharmaceuticals, Inc positions in Q1 2022 and 10 closed out, a net change of +8 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q1 2022 was VR Adviser, an estimated $2.75M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q1 2022 was BlackRock, an estimated $3.88M sold.
Based on aggregated 13F filings for Q1 2022.